Ethic Inc’s Royalty Pharma RPRX Stock Holding History

Ethic Inc’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Buy	4,597 +28	+0.6%	+$1.46K	﹤0.01%	1192
2026 Q1	$219K	Buy	+4,569	New	+$200K	﹤0.01%	1130
2025 Q1	–	Sell	-20,342	Closed	-$519K	–	1213
2024 Q4	$519K	Buy	20,342 +11,597	+133%	+$308K	0.01%	796
2024 Q3	$266K	Buy	+8,745	New	+$242K	0.01%	916
2024 Q2	–	Sell	-8,745	Closed	-$266K	–	1170
2024 Q1	$266K	Buy	+8,745	New	+$258K	0.01%	912
2023 Q1	–	Sell	-5,648	Closed	-$223K	–	998
2022 Q4	$223K	Buy	+5,648	New	+$236K	0.01%	798
2021 Q3	–	Sell	-6,638	Closed	-$272K	–	645
2021 Q2	$272K	Buy	+6,638	New	+$282K	0.03%	466

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ethic Inc's RPRX Position: Q2 2026 in Review

Ethic Inc increased its Royalty Pharma (RPRX) stake by 0.61% in Q2 2026, buying an estimated $1.46K and bringing the position to 4,597 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Ethic Inc first reported a position in RPRX in Q2 2021 and has held it in 7 quarters since. The position peaked at $519K in Q4 2024. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Ethic Inc held 4,597 shares of Royalty Pharma worth $258K as of Q2 2026.
Ethic Inc bought 28 Royalty Pharma shares in Q2 2026, an estimated $1.46K.
Royalty Pharma made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1192 holding.
Ethic Inc first reported a position in Royalty Pharma in Q2 2021 and has held it in 7 quarters since.
Ethic Inc's Royalty Pharma position peaked at $519K in Q4 2024.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.